- Home
- NCZ vs FULC Comparison
NCZ vs FULC Comparison
Compare NCZ & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCZ
- FULC
- Stock Information
- Founded
- NCZ 2003
- FULC 2015
- Country
- NCZ United States
- FULC United States
- Employees
- NCZ N/A
- FULC N/A
- Industry
- NCZ Finance Companies
- FULC Biotechnology: Pharmaceutical Preparations
- Sector
- NCZ Finance
- FULC Health Care
- Exchange
- NCZ Nasdaq
- FULC Nasdaq
- Market Cap
- NCZ 240.5M
- FULC 221.5M
- IPO Year
- NCZ N/A
- FULC 2019
- Fundamental
- Price
- NCZ $3.21
- FULC $3.96
- Analyst Decision
- NCZ
- FULC Hold
- Analyst Count
- NCZ 0
- FULC 10
- Target Price
- NCZ N/A
- FULC $7.44
- AVG Volume (30 Days)
- NCZ 533.0K
- FULC 1.0M
- Earning Date
- NCZ 01-01-0001
- FULC 02-25-2025
- Dividend Yield
- NCZ 12.16%
- FULC N/A
- EPS Growth
- NCZ N/A
- FULC N/A
- EPS
- NCZ N/A
- FULC N/A
- Revenue
- NCZ N/A
- FULC $80,871,000.00
- Revenue This Year
- NCZ N/A
- FULC $2,821.96
- Revenue Next Year
- NCZ N/A
- FULC N/A
- P/E Ratio
- NCZ N/A
- FULC N/A
- Revenue Growth
- NCZ N/A
- FULC 2987.86
- 52 Week Low
- NCZ $2.50
- FULC $2.86
- 52 Week High
- NCZ $3.15
- FULC $13.70
- Technical
- Relative Strength Index (RSI)
- NCZ 54.17
- FULC 41.64
- Support Level
- NCZ $3.06
- FULC $3.93
- Resistance Level
- NCZ $3.22
- FULC $5.17
- Average True Range (ATR)
- NCZ 0.06
- FULC 0.30
- MACD
- NCZ 0.01
- FULC -0.13
- Stochastic Oscillator
- NCZ 78.95
- FULC 3.97
About NCZ Virtus Convertible & Income Fund II of Beneficial Interest
Virtus Convertible & Income Fund II is a diversified, closed-end management investment company. Its investment objective is to provide total return through a combination of capital appreciation and high current income. Its portfolio of investments includes different sector investments such as in healthcare services, media, oil, gas and consumable fuels and others.
About FULC Fulcrum Therapeutics Inc.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.